Posaconazole Shortage: A Clinical Update for Providers

Posaconazole (Noxafil) remains a cornerstone of antifungal prophylaxis and treatment for immunocompromised patients. However, supply chain disruptions and formulation changes have created challenges for prescribers managing patients who depend on this medication. This article provides a clinical summary of the current shortage landscape, practical guidance for managing affected patients, and considerations for therapeutic alternatives.

Current Supply Status (2026)

Delayed-Release Tablets (100 mg)

Generic Posaconazole delayed-release tablets are available from multiple manufacturers and represent the most consistently available oral formulation. Periodic spot shortages at individual pharmacies have been reported, but overall supply has been relatively stable. Multiple generic manufacturers, including Lannett and others, are producing this formulation.

Immediate-Release Oral Suspension (Discontinued)

The immediate-release (IR) oral suspension (40 mg/mL) was removed from the US market in 2024. This has had significant clinical implications for patients who cannot swallow tablets — particularly pediatric patients, patients with mucositis, and those with dysphagia. Providers should be aware that legacy orders for the IR suspension may still exist in electronic medical records and should be updated.

PowderMix Delayed-Release Oral Suspension

Noxafil PowderMix (powder for delayed-release oral suspension) has been introduced as a replacement for the discontinued IR suspension. Key clinical considerations:

• The delayed-release oral suspension is not dose-equivalent to the former IR suspension
• Dosing follows the delayed-release tablet regimen (300 mg loading on Day 1, then 300 mg once daily)
• Absorption is less dependent on food intake and gastric pH compared to the former IR suspension
• Therapeutic drug monitoring (TDM) remains advisable during the transition period

IV Formulation (300 mg/16.7 mL)

The IV formulation remains available for inpatient use. It contains the cyclodextrin vehicle betadex sulfobutyl ether sodium (SBECD), which can accumulate in patients with moderate-to-severe renal impairment (CrCl <50 mL/min). Monitor serum creatinine in these patients and transition to oral therapy when feasible.

Clinical Impact of Supply Disruptions

Interruptions in Posaconazole prophylaxis can have serious consequences for high-risk patient populations:

• Hematologic malignancy patients on intensive chemotherapy with prolonged neutropenia face increased risk of invasive aspergillosis and mucormycosis during gaps in prophylaxis
• Hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) require ongoing antifungal prophylaxis; interruptions may precipitate breakthrough infections
• Solid organ transplant recipients on immunosuppressive regimens are vulnerable to opportunistic fungal infections if prophylaxis is interrupted

Data from clinical trials (Cornely et al., NEJM 2007; Ullmann et al., NEJM 2007) demonstrated the superiority of Posaconazole prophylaxis over Fluconazole or Itraconazole in preventing invasive fungal infections and reducing mortality in high-risk patients.

Therapeutic Alternatives: A Clinical Comparison

When Posaconazole is unavailable, the choice of alternative depends on the clinical indication, patient risk factors, and formulary availability.

Voriconazole (Vfend)

• Spectrum: Aspergillus, Candida, Fusarium, Scedosporium; does not cover Mucorales
• Evidence for prophylaxis: Limited evidence compared to Posaconazole; not FDA-approved for prophylaxis
• Monitoring: Requires therapeutic drug monitoring; target trough 1–5.5 mcg/mL
• Key concerns: Hepatotoxicity, visual disturbances, photosensitivity, QTc prolongation, more CYP450 interactions (2C19, 2C9, 3A4)
• Cost: Generic available; generally affordable

Isavuconazonium Sulfate (Cresemba)

• Spectrum: Aspergillus, Mucorales, Candida — the closest match to Posaconazole's spectrum
• Evidence: FDA-approved for treatment of invasive aspergillosis and mucormycosis; off-label use for prophylaxis is growing
• Monitoring: TDM not routinely required but may be considered in select populations
• Key concerns: Shortens QTc interval (avoid in short QT syndrome); hepatotoxicity; fewer drug interactions than Posaconazole
• Cost: Brand-name only; significantly more expensive than generic Posaconazole or Voriconazole

Itraconazole (Sporanox)

• Spectrum: Aspergillus (limited), Candida, endemic mycoses
• Evidence for prophylaxis: Shown to be inferior to Posaconazole in the Cornely et al. trial for prophylaxis in AML/MDS patients
• Monitoring: TDM recommended; erratic absorption with capsule formulation
• Key concerns: Negative inotropic effect (avoid in heart failure); less reliable bioavailability; extensive drug interactions
• Cost: Generic available; affordable

Amphotericin B (Liposomal — AmBisome)

• Spectrum: Broad-spectrum including Mucorales; reserved for treatment rather than prophylaxis
• Route: IV only (for liposomal formulation)
• Key concerns: Nephrotoxicity, infusion-related reactions; not practical for outpatient prophylaxis
• Role: Consider for inpatient empiric therapy when oral azoles are unavailable

Practical Management Strategies

For Outpatient Settings

1. Identify affected patients proactively. Review patient lists to identify those on Posaconazole and contact them before their current supply runs out.
2. Direct patients to availability tools. MedFinder for Providers can help identify pharmacies with current Posaconazole stock.
3. Verify formulation and dosing. If switching from the discontinued IR suspension to tablets or PowderMix, ensure dosing is updated appropriately. The formulations are not interchangeable.
4. Coordinate with specialty pharmacies. Patients' insurance plans may require use of specific specialty pharmacies. Confirm that these pharmacies have Posaconazole in stock before sending prescriptions.
5. Implement therapeutic drug monitoring. When switching formulations or alternatives, check trough levels to confirm therapeutic concentrations.

For Inpatient Settings

1. Update EMR order sets. Remove references to the discontinued IR oral suspension and update to current formulations and dosing.
2. Coordinate with pharmacy and therapeutics (P&T) committees. Establish institutional protocols for Posaconazole substitution when supply is limited.
3. Plan discharge transitions carefully. Confirm outpatient pharmacy availability before transitioning patients from IV to oral Posaconazole at discharge.

Patient Assistance and Financial Considerations

Cost can be a barrier to adherence, even when supply is available. Provider resources include:

• Merck Patient Assistance Program (merckhelps.com): Provides Noxafil at no cost to eligible uninsured or underinsured patients
• Prior authorization support: Most insurance plans require PA for Posaconazole; ensure documentation includes ICD-10 codes supporting medical necessity
• Discount programs: Generic Posaconazole tablets can be obtained for approximately $187–$250 for a 90-tablet supply through programs like GoodRx, significantly less than the $3,600+ cash price

For more on helping patients with costs, see: How to Help Patients Save Money on Posaconazole: A Provider's Guide.

Shortage Monitoring Resources

• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages
• FDA Drug Shortage Database: FDA.gov drug shortages
• MedFinder for Providers: medfinder.com/providers — real-time pharmacy stock checks

Summary

The Posaconazole supply landscape in 2026 requires proactive management. The discontinuation of the IR oral suspension, limited generic tablet manufacturers, and specialty drug distribution challenges all contribute to ongoing availability concerns. Providers should proactively identify at-risk patients, use real-time availability tools, and have evidence-based alternative regimens ready. When switching is necessary, Isavuconazonium provides the closest spectrum match, while Voriconazole offers a cost-effective alternative for patients primarily at risk for Aspergillus.

Related provider resources:

• How to Help Your Patients Find Posaconazole in Stock
• How to Help Patients Save Money on Posaconazole